Evaxion (NASDAQ: EVAX) unveils AI-Immunology data for glioblastoma vaccines

Rhea-AI Filing Summary

Evaxion A/S, a clinical-stage TechBio company, reports new data from its AI-Immunology™ platform showing it can design personalized cancer vaccines for glioblastoma, a deadly brain cancer with limited treatment options.

Working with Duke University School of Medicine, Evaxion identified endogenous retrovirus (ERV)-derived antigens and additional neoantigens in glioblastoma tumor samples. ERVs, which are present in tumors but absent in normal tissue, are highlighted as an attractive new antigen source. Bioinformatic and experimental data indicate ERV-derived antigens can trigger immune responses and may help overcome challenges linked to low mutational burden in glioblastoma. The data will be presented at the American Association for Cancer Research Annual Meeting in San Diego on April 22, 2026.

Key Figures

AACR presentation date: April 22, 2026 Poster number: 6975 Poster session time CST: 9am-12pm CST +2 more

5 metrics

AACR presentation date April 22, 2026 Poster presentation at AACR Annual Meeting in San Diego

Poster number 6975 AACR Annual Meeting poster identifier for glioblastoma data

Poster session time CST 9am-12pm CST AACR session time for Evaxion glioblastoma presentation

Poster session time CET 16-19 CET Corresponding European time for AACR poster session

Evaxion team size +40 experts Described team covering discovery through clinical development

Key Terms

endogenous retrovirus (ERV)-derived antigens, neoantigens, low mutational burden, personalized vaccines, +2 more

6 terms

endogenous retrovirus (ERV)-derived antigens medical

"to identify endogenous retrovirus (ERV)-derived antigens in tumor samples from multiple glioblastoma patients"

neoantigens medical

"glioblastoma patients, who generally have few neoantigens to target due to low mutational burden"

Neoantigens are new protein fragments that appear on the surface of diseased cells, most often cancer cells, because of changes in their DNA; the immune system can recognize these as foreign. For investors, neoantigens matter because they are targets for precision therapies and vaccines that aim to teach the immune system to attack only diseased cells—think of them as unique fingerprints that enable treatments to be more specific and potentially more effective, which can drive clinical and commercial value.

low mutational burden medical

"few neoantigens to target due to low mutational burden"

personalized vaccines medical

"providing a strong Proof-of-Concept for personalized vaccines incorporating ERV-derived antigens"

TechBio company financial

"Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines"

AI-Immunology™ platform technical

"developing novel vaccines with its pioneering AI-Immunology™ platform"

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On April 17, 2026, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits

Exhibit No.		Description
99.1		New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: April 17, 2026		By:	/s/ Helen Tayton-Martin
			Helen Tayton-Martin
			Chief Executive Officer

EXHIBIT 99.1

New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma

• Data analysis conducted in collaboration with a leading academic medical center shows that AI‑Immunology™ enables vaccine design also for the deadly brain cancer, glioblastoma
• Uniquely, the platform can identify a novel source of targets to include in glioblastoma cancer vaccines, potentially enhancing their efficacy
• Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting
  

COPENHAGEN, Denmark, April 17, 2026 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform’s ability to also potentially develop vaccines for glioblastoma (brain cancer).

The data, which will be presented at the AACR Annual Meeting in San Diego, California, on April 22, 2026, is another confirmation of how AI-Immunology™ can be applied across a range of different cancers as well as other diseases.

Evaxion has collaborated with researchers at Duke University School of Medicine to identify endogenous retrovirus (ERV)-derived antigens in tumor samples from multiple glioblastoma patients to include in vaccines to treat the deadly brain cancer, for which limited therapeutic options exist.

ERVs are tumor antigens from the dark genome. These antigens are present in tumors but absent in normal tissue, making them highly attractive targets for cancer vaccines. AI-Immunology™ has unique capabilities in identifying ERVs and this opens a whole new source of antigens, which can potentially greatly improve the efficacy of cancer vaccines for glioblastoma patients, who generally have few neoantigens to target due to low mutational burden.

In addition to the ERV-derived antigens, we also identified neoantigens of sufficient quality to include in a vaccine in the majority of patients

“We are excited by these new findings confirming that AI-Immunology™ is a unique platform for designing vaccines for many different cancer types, combining neoantigens with other types of antigens. This holds great potential for improving vaccine efficacy, and we are looking forward to discussing the data with both scientific stakeholders and potential business partners at the AACR Annual Meeting,” says Birgitte Rønø, CSO of Evaxion.

Strong Proof-of-Concept
The new findings include bioinformatic analysis profiling ERV expression in patient tumor samples and vaccine design feasibility assessment as well as experimental data demonstrating immunologic responses of the discovered ERV antigens. They show that ERVs constitute a relevant antigen source that may overcome limitations imposed by low mutational burden, providing a strong Proof-of-Concept for personalized vaccines incorporating ERV-derived antigens.

“There is a dire need for better treatment options for glioblastoma, which is refractory to immunotherapy due to low mutational burden and paucity of canonical neoantigens. We are encouraged to have found a new tumor-specific antigen source in ERVs that can be targeted by vaccines alongside mutation-derived epitopes,” says Professor Mustafa Khasraw, MD, who studies tumor immunobiology at Duke University School of Medicine.

AACR presentation details
Abstract title: Endogenous retrovirus-derived neoantigens enable a personalized cancer vaccine strategy for glioblastoma
Poster#: 6975
Session category: Immunology
Session title: Novel Models of Immunotherapy Response
Location: Poster section 8
Date/Time: April 22, 2026, at 9am-12pm CST/16-19 CET 
Presenter: Megan Benz, Duke University Medical Center

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

FAQ

What did Evaxion (EVAX) announce about its AI-Immunology platform in glioblastoma?

Evaxion reported new data showing its AI-Immunology platform can design personalized cancer vaccines for glioblastoma. The work identified tumor-specific antigens, supporting the platform’s scalability across cancer types and its potential application in this hard-to-treat brain cancer.

How is Evaxion (EVAX) using endogenous retrovirus (ERV)-derived antigens in glioblastoma?

Evaxion and Duke University researchers identified ERV-derived antigens in glioblastoma tumor samples to include in vaccines. Because ERVs appear in tumors but not normal tissue, they are described as highly attractive targets for cancer vaccines in this indication.

Why are glioblastoma patients a focus for Evaxion’s AI-Immunology platform?

Glioblastoma is highlighted as a deadly brain cancer with few effective therapies and low mutational burden. This makes traditional neoantigen strategies difficult, so Evaxion is exploring ERV-derived antigens and high-quality neoantigens to broaden vaccine targets for these patients.

What evidence supports Evaxion’s glioblastoma vaccine concept from this 6-K?

The new findings include bioinformatic profiling of ERV expression in tumor samples, assessment of vaccine design feasibility, and experimental data showing immune responses to ERV antigens. Together, they provide what Evaxion calls strong proof-of-concept for personalized vaccines using ERV-derived antigens.

Where and when will Evaxion present the new glioblastoma data?

Evaxion will present the glioblastoma data at the American Association for Cancer Research Annual Meeting in San Diego, California. The poster session is scheduled for April 22, 2026, from 9am to 12pm CST, in poster section 8.

Who are Evaxion’s key collaborators on the glioblastoma vaccine work?

Evaxion collaborated with researchers at Duke University School of Medicine. They helped identify ERV-derived antigens and neoantigens in tumor samples from multiple glioblastoma patients, supporting the personalized vaccine strategy described in the announcement.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 8.2 KB